I mplantable cardioverter-defibrillators (ICDs) used in appropriately selected patients at high risk of sudden cardiac death are associated with reduction in arrhythmic death. 1 Recommendations for ICDs are based on large randomized, controlled trials, which often enroll highly selected patients who are often young with few comorbidities. In contrast, the average patient with heart failure and severe left ventricular systolic dysfunction is aged >65 years with multiple comorbidities. With the aging population, the number of elderly patients being considered for ICD implantation is increasing, and an estimated 28% of those deemed potentially eligible by conventional criteria are octogenarians. 2 However, with advancing age and comorbidity burden, the relative contribution of nonarrhythmic causes of death may increase, 3, 4 potentially attenuating the benefits of ICD therapy. Current guidelines do not specifically address the appropriateness or prognosis of ICD implantation with advanced age. 1, 5, 6 recipients. We also investigated clinical factors associated with mortality to provide guidance when considering candidates for ICD implantation in older age strata.
Methods The Ontario ICD Database
The design and methodology of the Ontario ICD Database have been described previously. 7 The Ontario ICD Database prospectively collected information on patient characteristics, device indication, and implant-related data from all 10 adult defibrillator implantation centers in the province. Data were collected by cardiac electrophysiologists and trained research coordinators at ICD implantation centers, who entered real-time data into a secure, firewall-and password-protected Web-based registry. Clinical and device-related events occurring during follow-up were captured during defibrillator clinic visits at either the implanting hospital or peripheral device clinics. 7 The Ontario ICD Database used continuous data quality assessments via automated logic and range checks including dates of all events, notification of uncoded data elements, and random site audits performed in 5% of patients, ensuring κ statistic or crude agreement rates ≥0.7.
Patients
We examined patients undergoing de novo ICD implantation for primary or secondary prevention between February 2007 and September 2010. Patient data were collected at initial evaluation, at the time of ICD implantation, and at each device clinic follow-up. Data collection was mandated by the Ontario Ministry of Health and Long-term Care, and therefore we captured data on all patients undergoing defibrillator implantation at a province-wide level. Under Ontario health information privacy legislation, data were acquired on all registry patients without informed consent, and therefore participation bias was precluded. We compared patients in the following age categories: 18 to 49 (reference category), 50 to 59, 60 to 69, 70 to 79, and ≥80 years. In descriptive analyses, those aged 18 to 59 years were grouped together because of small cell sizes in the <50-years age category. In this analysis, we excluded patients who were cardiac transplantation candidates and those with congenital heart disease, hypertrophic cardiomyopathy, infiltrative diseases, Brugada syndrome, arrhythmogenic right ventricular dysplasia, congenital long-QT syndrome, or other inherited arrhythmia syndromes.
Administrative Data Sources
Using the patient's unique, encrypted health card number, we linked the following data sources to the clinical data in the Ontario ICD Database. The Canadian Institute for Health Information Discharge Abstract Database was used to identify hospitalizations, and the Registered Persons Database was used to determine occurrence of death. Cardiac admissions were identified by International Classification of Diseases, Tenth Revision (Canada) codes I11, I20-I25, I30-I39, I41-I52, I01-I02, I05-I09, I95, I97, and R57.0. Cardiovascular hospitalizations included all cardiac admission codes, including International Classification of Diseases, Tenth Revision (Canada) codes I60-I69, I10, I12, I13, I15, I26-I28, I57, I70-I74,  I77-I82, G45 , G46, R02, and R55. All other hospitalizations were designated as noncardiovascular.
Outcomes
The primary outcomes were (1) total mortality and (2) appropriate ICD shock for electrical therapy of ventricular tachyarrhythmia. Additional secondary outcomes included (1) appropriate therapy with either shock or antitachycardia pacing, (2) inappropriate shocks, (3) device-related complications within 45 days of implantation, and (4) hospitalizations. ICD therapies were classified as appropriate or inappropriate by the on-site treating physician and were reviewed by an external panel of 3 cardiac electrophysiologists, demonstrating excellent agreement for appropriate shock (κ statistic=0.928) and therapy (κ statistic=0.901) with crude agreement rates >99% for both outcomes. 8 To explore conditions that contributed to mortality, we identified all hospitalizations that occurred within 30 days before death and determined the primary reason for the hospital admission. Hospitalizations leading to death were categorized as cardiovascular (subcategory cardiac) or noncardiovascular. Complications were defined as major or minor on the basis of previously described consensus definitions. [9] [10] [11] In general, major complications required hospitalization, lead or device revision, or substantive parenteral therapy.
Statistical Analysis
Data are presented as mean±SD for continuous variables or proportions for dichotomous variables. Comparisons were performed across age groups with the use of global tests of significance, such as ANOVA for continuous covariates and the χ 2 statistic for categorical variables. Rates of appropriate ICD shock, appropriate device-delivered at University of Toronto on March 13, 2015 http://circ.ahajournals.org/ Downloaded from therapies, and inappropriate shocks were determined as rates per 100 person-years of follow-up with censoring at death. We used regression methods described by Harrell, 12 in which potentially clinically important predictors of outcome with P<0. 25 were considered for entry into a Fine and Gray competing risk timeto-event model. Covariates were retained in the final nonparsimonious multivariable model if the P value was <0.20 for competing risk of either death or appropriate ICD shock. All models were adjusted for sex irrespective of its nominal statistical significance. Potential variables considered in multivariable competing risks analysis of mortality versus appropriate ICD shock included New York Heart Association class, left ventricular ejection fraction (LVEF), QRS duration, cardiac resynchronization therapy, type of cardiomyopathy, family history of sudden cardiac death, syncope, atrial fibrillation, diabetes mellitus, hypertension, transient ischemic attack or stroke, peripheral vascular disease, dialysis, chronic obstructive pulmonary disease, active cancer, blood pressure, serum sodium, hemoglobin, blood urea nitrogen, glomerular filtration rate estimated with Modification of Diet in Renal Disease equation, 13 and medications (selected definitions are shown in the Appendix in the online-only Data Supplement). 14 Predictors of total death for use in noncompeting time-to-event analyses were identified by multiple Cox regression, retaining covariates with P<0.05. In the absence of an outcome event, time-to-event analyses were censored on the last follow-up date of December 15, 2011. Cumulative incidence curves were constructed separately for primary and secondary prevention cohorts. All tests of significance were 2-tailed, with P<0.05 considered statistically significant. Statistical analyses were performed using SAS version 9.2 (SAS Institute Inc, Cary, NC) and with R for Fine and Gray competing risks analysis.
Results

Study Population
Among 6079 patients who underwent de novo ICD implantation, 5399 met study inclusion criteria. Indications for ICD implantation were primary (n=3939) and secondary (n=1460) prevention ( Figure 1 ), with mean ages at implantation of 65.2±10.7 and 66.5±11.2 years, respectively (80.9% men). Elderly patients aged 70 to 79 and ≥80 years accounted for 31.6% and 8.0% of all ICD implantations, respectively. Among those referred for a device, ICD implantation rates were 81.3% (18-49 years), 80.6% (50-59 years), 81.9% (60-69 years), 81.5% (70-79 years), and 72.3% (≥80 years) overall (P=0.008), with significantly higher rates of refusal among octogenarians ( Table I in Tables 1 and 2. LVEF ≤35% was present among 93.0% of primary and 59.3% of secondary prevention patients. Ischemic heart disease accounted for 70.4% of primary and 81.5% of secondary prevention patients, increasing in prevalence with age. Elderly patients were more likely to exhibit atrial fibrillation, hypertension, previous stroke, reduced kidney function, and wider QRS duration, but LVEF and left atrial dimension were similar across age groups. Most patients were in receipt of high rates of evidence-based cardiovascular medications.
Device-Related Outcomes
There were 373, 744, and 164 primary prevention patients who received an appropriate shock, appropriate therapy, and inappropriate therapy, whereas 284, 498, and 77 secondary prevention patients received these types of therapies, respectively ( Table 3) . Rates of appropriate shock were nonsignificantly lower with older age, as follows: 6.7 (18-49 years), 5.2 (50-59 years), 5.0 (60-69 years), 5.1 (70-79 years), and 4.2 (≥80 years) events per 100 person-years for primary prevention (P=0.139). Similar rates of appropriate shocks were observed among secondary prevention ICD recipients, as follows: 11.4 (18-49 years), 10.3 (50-59 years), 13.9 (60-69 years), 11.2 (70-79 years), and 11.9 (≥80 years) events per 100 person-years (P=0.993). Appropriate ICD therapy was successful in terminating the arrhythmia in 97% of primary and 96% of secondary prevention patients. Inappropriate shock rates were <3.5% overall but tended to be slightly higher in younger primary prevention patients (Table 3) . Early major 45-day complication rates were similar between age strata (Table 3 ).
Mortality
During 7688 person-years of follow-up, there were 415 deaths among primary prevention ICD recipients. Among secondary prevention patients, there were 194 deaths during 2761 person-years of follow-up. Deaths increased with older age after both primary and secondary prevention implantations; however, the incremental mortality effect was more pronounced in the secondary prevention group (Table 4 ; both P<0.001).
Cardiovascular and noncardiovascular hospitalizations that ended in death increased with age (Table 4 ). Older age was a significant predictor of death in multivariable analysis of primary and secondary prevention ICDs (Table II in 
Competing Risk Analysis
Cumulative incidence plots of appropriate shock competing with death for primary and secondary prevention demonstrated higher risks of death among older ICD recipients but lesser separation of appropriate shocks according to age group (Figures 2 and 3 and Table III in the online-only Data Supplement). Competing risk analyses of death competing with occurrence of appropriate shocks examining the impact of age are shown in Table 5 (full models are shown in Tables IV and V in the online-only Data Supplement). The adjusted hazard ratio for appropriate shock competing with death decreased nonsignificantly, with no significant trend for older age groups among primary (P=0.130) and secondary (P=0.810) prevention ICD recipients. The hazard ratio for death increased with older age category (P<0.001), with significant increases beginning in the 60-to 69-year age group for primary prevention ICD recipients and ≥80-year age group for secondary prevention ICD recipients.
Factors Affecting Mortality
Primary prevention ICD recipients aged ≥60 years and secondary prevention ICD patients aged ≥80 years experienced increased mortality risk on multivariable analysis (Table 5 ). Parsimonious multivariable predictors of death are shown in Table II predictors of mortality common to both groups included New York Heart Association class, peripheral vascular disease, and use of loop diuretics. Syncope, reduced glomerular filtration rate, and left atrial size were predictors of mortality in primary prevention patients. There was no significant interaction between age and cardiac resynchronization therapy versus non-cardiac resynchronization therapy device type in multivariable-adjusted models for death among primary (P interaction =0.149) and secondary (P interaction =0.520) prevention defibrillator recipients. Death after appropriate shock was highest among elderly primary and secondary prevention patients (Figures 4 and  5) . After an appropriate shock, the adjusted hazard ratios for death per decade were 1.28 (95% confidence interval, Table II in the online-only Data Supplement for model covariates).
Discussion
It has been postulated that elderly patients with left ventricular systolic dysfunction or prior ventricular arrhythmias may not derive the same benefit from ICD implantation as younger patients. 15, 16 Information on the utilization and effectiveness of ICD implantation in the elderly for prevention of sudden arrhythmic death is increasingly important with the aging population. In this population-based registry, we found that elderly patients undergoing primary or secondary prevention ICD implantation experienced rates of appropriate and inappropriate shock similar to those of their younger counterparts. Although 45-day complications were not increased, deaths increased significantly with older recipient age.
Previous randomized studies have reported divergent results on the benefit of ICDs in the elderly. In a Multicenter Automatic Defibrillator Implantation trial II (MADIT-II) substudy evaluating 204 elderly patients (aged >75 years) with ischemic cardiomyopathy, there was a nonsignificant trend toward benefit with ICD therapy (hazard ratio, 0.56; 95% confidence interval, 0.29-1.08; P=0.08). 17 Subgroup analysis of patients aged >65 years in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) and Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) studies also showed little mortality benefit. 18, 19 A meta-analysis of secondary prevention trials (Cardiac Arrest Study Hamburg [CASH], Antiarrhythmics Versus Implantable Defibrillators [AVID], Canadian Implantable Defibrillator Study [CIDS]) showed that patients aged >75 years did not derive all-cause mortality benefit with a hazard ratio of 1.06 (95% confidence interval, 0.69-1.64; P=0.79). 15 However, these randomized trials enrolled selected patient subsets and were not drawn from population-based cohorts. The underrepresentation of elderly patients in randomized trials, varying thresholds for defining advanced age, and inconsistent results necessitated an in-depth examination of a large population registry with outcomes reported to guide clinical decisions.
Our study extends the existing literature by providing further insights on the outcomes of elderly ICD recipients. A retrospective review of new ICD implantations between 1997 and 2003 with the use of a large administrative at University of Toronto on March 13, 2015 http://circ.ahajournals.org/ Downloaded from database showed that age >75 years, recent-onset heart failure, and noncardiac comorbidities were independent predictors of death. 3 However, this study did not distinguish primary and secondary prevention indications and lacked important clinical information, including laboratory values, LVEF, and New York Heart Association class. Tsai et al 20 examined a large population of primary prevention ischemic cardiomyopathy patients from the National Cardiovascular Data ICD Registry and found that age was only a weak predictor of nonarrhythmic death after covariate adjustment, but only in-hospital outcomes were reported. Epstein et al 21 evaluated outcomes from the Advancements in ICD Therapy Registry and found that noncardiac death was more frequent but the sudden cardiac death rate was similar among elderly patients. Chan et al 22 compared a prospective cohort of 123 ICD recipients aged >75 years with 146 patients without the device and showed a significant reduction in mortality. Koplan et al 23 demonstrated shorter median survival among octogenarian ICD recipients at 4.2 years compared with 7 years in patients aged 60 to 70 years. However, these prior studies did not stratify by prophylactic indication, nor did they systematically examine prognosis after device implantation or appropriate ICD shock. In addition, data on ICD therapies, cause of death, and complication rates were not explored. Prior observational studies have also evaluated small samples at single centers and lacked sufficient clinical data to control for confounders. 24, 25 The current report is novel because the data were collected in a prospective fashion with detailed longitudinal follow-up. Outcomes were determined bimodally with the use of a combination of both clinical assessments and passive follow-up through well-established administrative databases. We therefore comprehensively captured important outcomes, including death, hospitalization, appropriate ICD therapy, and complications. The registry was mandated by the single payer of healthcare services in Ontario, and participation from all ICD implantation centers was required. Thus, we were able to study all patients in a robust multicenter fashion irrespective of age and comorbidities. To our knowledge, this is one of the largest prospective and longitudinal registries of ICD implantation in a contemporary cohort of elderly patients.
All-cause annualized mortality rate was 5.4% in the primary prevention cohort, which is similar to that reported in SCD-HeFT but lower than the 7.5% to 8.5% rate reported in other primary prevention trials. 18, 26, 27 The annual mortality rate of 7% for the secondary prevention group was lower than previously reported randomized trial data. 28, 29 Improved treatment of heart failure and coronary disease in the last decade along with better patient selection may account for the lower observed mortality rate. Elderly patients demonstrated a higher rate of all-cause death, particularly in the secondary prevention cohort. The appropriate shock rate of 5% for primary prevention was similar to the rate reported in the literature, but the secondary prevention shock rate of 12% was lower than that reported previously. 29, 30 This may be explained by a trend toward more thoughtful programming and concomitant use of antiarrhythmic medication to avert unnecessary shocks. After we accounted for clinical differences and comorbidities, the rate of appropriate shock was not different for elderly patients, suggesting that they derive benefit in reduction of arrhythmic death similar to that in younger patients. The effect of an appropriate shock on prognosis in elderly patients has not been systematically examined previously. In our study, appropriate shocks were successful in terminating acute malignant arrhythmia in virtually all patients, and almost all elderly patients survived >30 days after the shock. This refutes the argument that elderly patients are more susceptible to unsuccessful shocks or electromechanical dissociation after ICD shock, coined previously as cardiac annihilation. 31 The annualized inappropriate shock rate of ≈1.5% to 3.5% per year in our study was similar to a rate of 18% at 5 years reported in a recent study, 32 although prior estimates up to 24% over 3 years have been demonstrated. 33 This is likely related to better rhythm discrimination algorithms, more aggressive *Primary prevention models adjusted for sex and other significant covariates: New York Heart Association class, ischemic vs nonischemic disease, syncope, peripheral vascular disease, chronic lung disease, current smoking, glomerular filtration rate, QRS duration, left atrial size, angiotensin-converting enzyme inhibitor or receptor blocker, and loop diuretic use. †Secondary prevention models adjusted for sex and other significant covariates: New York Heart Association class, ischemic vs nonischemic disease, syncope, diabetes mellitus, hypertension, stroke or transient ischemic attack, peripheral vascular disease, chronic lung disease, hemoglobin, glomerular filtration rate, QRS duration, left ventricular ejection fraction, angiotensinconverting enzyme inhibitor or receptor blocker, and loop diuretic use.
use of antitachycardia pacing, and elimination of unnecessary therapy zones in primary prevention devices. Misdiagnosis of supraventricular tachycardia has accounted for the vast majority of inappropriate ICD shocks in previous studies. [32] [33] [34] The higher incidence of atrial fibrillation in our elderly population did not result in a greater number of inappropriate ICD shocks compared with younger patients. Indeed, there were more inappropriate shocks in younger patients, likely as a result of sinus tachycardia. This verifies a report by van Rees et al 32 that determined that age <70 years was a multivariate predictor of inappropriate shock. The impact of inappropriate therapy on mortality was not evaluated and warrants further investigation. Early complications were not increased in elderly patients and were consistent with those found in a prior report. 11 The findings from this study suggest that ICD implantation in the elderly requires individualized consideration. Age was an independent predictor of death in our contemporary cohort of ICD recipients; however, other factors that also confer increased mortality risk may also be associated with older age. Lee et al 11 used administrative data to show that survival after ICD implantation was inversely related to an increasing number of comorbidities. The MADIT-II Investigators suggested that ICD efficacy for primary prevention in ischemic cardiomyopathy is U-shaped, with attenuated benefit in the lowestand highest-risk subgroups. 35 Age >70 years was considered a risk factor in this model, suggesting that all elderly patients are classified as at least intermediate risk. Buxton et al 36 performed a similar risk stratification using the Multicenter Unsustained Tachycardia Trial (MUSTT) data set and found that New York Heart Association class, conduction disturbance, history of heart failure, LVEF, atrial fibrillation, and age were predictors of mortality. We found differential impacts of age in primary and secondary prevention groups, which may reflect differences in risk factor profile and the clinically distinct nature of patients based on device indication.
The limitations of our study should be noted. All patients approved for ICD implantation in Ontario were assessed by board-certified electrophysiologists, who made decisions on the basis of conventional evidence-based indications. The generalizability of our findings to other jurisdictions with more liberal policies of ICD selection is unknown. Although we were unable to compare elderly ICD recipients with nonimplanted controls, our study suggests that the absolute benefit of implanted defibrillators will be diminished in the elderly unless those with fewer concomitant factors contributing to mortality can be selected. We were only able to indirectly determine the mode or cause of death by linkages with administrative hospitalization databases, but we anticipate that deaths were likely primarily nonarrhythmic because all patients were implanted with ICDs, which are highly effective in reducing death from arrhythmia. Finally, although our study is informative about the age-related risk profile of ICD recipients, it should only be used in conjunction with good clinical judgment when medical decisions are made.
Our study represents one of the largest age-stratified systematic evaluations of ICD implantation in primary and secondary prevention patients and explores the risk-benefit relationship in an increasingly important aging population. Although elderly patients with ICDs are at increased risk of death compared with their younger counterparts, the absolute mortality risk is modest when patients are carefully selected. Elderly individuals also received similar rates of appropriate shock without increased risk of adverse events. These results may serve as a guide for discussion when elderly ICD candidates are evaluated. Consideration of comorbidities and known predictors of mortality will help to identify patients who are most likely to derive relative benefit. In sum, older age does not diminish the likelihood of receiving appropriate device-delivered electrical therapies, but elderly patients should be evaluated carefully for comorbidities that may increase the relative risk of nonarrhythmic mortality. 
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